Previous 10 | Next 10 |
Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection PR Newswire Based on observed aggregate blinded data the Company has determined that both treatments, ibezapolstat ...
Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress PR Newswire ...
Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023 PR Newswire STATEN ISLAND, N.Y. , Aug. 22, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinica...
2023-08-14 13:18:02 ET Acurx Pharmaceuticals, Inc. (ACXP) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Rob Shawah - CFO Dave Luci - President and CEO Conference Call Participants Ed Arce - HC. Wainwright Michael Oku...
2023-08-14 11:30:17 ET Acurx Pharmaceuticals press release ( NASDAQ: ACXP ): Q2 GAAP EPS of -$0.28. The Company ended the second quarter with cash totaling $9.1 million compared to $9.1 million as of December 31, 2022. For further details see: Acurx Pharmaceutica...
2023-08-14 07:25:38 ET Acurx Pharmaceuticals press release ( NASDAQ: ACXP ): Q2 GAAP EPS of -$0.28 misses by $0.07 . The company ended the second quarter with cash totaling $9.1 million compared to $9.1 million as of December 31, 2022. For further details see: ...
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , Aug. 14, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage bio...
Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , July 24, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceu...
2023-07-07 15:00:36 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- New to The Street , an FMW Media production, will air its corporate interviews, episodes 486 and 487, on Newsmax and the FOX Business Network . The Following Corporate interviews will air on Newsmax, episode 486, Saturd...
News, Short Squeeze, Breakout and More Instantly...
Acurx Pharmaceuticals Inc. Company Name:
ACXP Stock Symbol:
NASDAQ Market:
Acurx Pharmaceuticals Inc. Website:
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome PR Newswire STATEN ISLAND, N.Y. , July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:...
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "...
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference PR Newswire Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including inc...